DrugPatentWatch Database Preview
Rempex Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for REMPEX PHARMS, and when can generic versions of REMPEX PHARMS drugs launch?
REMPEX PHARMS has two approved drugs.
There are seven US patents protecting REMPEX PHARMS drugs.
There are sixty-eight patent family members on REMPEX PHARMS drugs in twenty-eight countries and twenty-one supplementary protection certificates in eleven countries.
Summary for Rempex Pharms
| International Patents: | 68 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Rempex Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 10,561,675 | Start Trial | Start Trial | ||||
| Rempex Pharms | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | 9,084,802 | Start Trial | Start Trial | ||||
| Rempex Pharms | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | 9,278,105 | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 8,680,136 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Rempex Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | E033161 | Start Trial |
| Australia | 2011252919 | Start Trial |
| Colombia | 6650346 | Start Trial |
| Lithuania | 3412676 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Rempex Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2603514 | CA 2019 00016 | Denmark | Start Trial | PRODUCT NAME: VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT HERAF; REG. NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | C201930022 | Spain | Start Trial | PRODUCT NAME: COMBINACION DE VABORBACTAM, Y/O UNA SAL Y/O UN HIDRATO DEL MISMO, Y MEROPENEM, Y/O UNA SAL Y/O UN HIDRATO DEL MISMO, EN PARTICULAR MEROPENM TRIHIDRATO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1334; DATE OF AUTHORISATION: 20181120; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1334; DATE OF FIRST AUTHORISATION IN EEA: 20181120 |
| 3412676 | PA2020519 | Lithuania | Start Trial | PRODUCT NAME: VABORBAKTAMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO BEI MEROPENEMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO, YPAC MEROPENEMO TRIHIDRATO, DERINYS; REGISTRATION NO/DATE: EU/1/18/1334 20181120 |
| 2603514 | 300977 | Netherlands | Start Trial | PRODUCT NAME: EEN COMBINATIE VAN VABORBACTAM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, EN MEROPENEM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, IN HET BIJZONDER MEROPENEM TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
